~111 spots leftby Jul 2028

OKN4395 + Pembrolizumab for Solid Tumors (INVOKE Trial)

Recruiting in Palo Alto (17 mi)
+2 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: Epkin
No Placebo Group
Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. This study will be split into 2 parts. Part 1a will look at multiple doses of OKN4395 either alone (monotherapy) or with pembrolizumab (combination therapy) administered on day 1 of each 21-day cycle in patients with solid tumors until the participant has disease progression or discontinues for any reason. The dose of OKN4395 will be increased, after each group of 3 or more patients completes their first 3 weeks of treatment and their data is evaluated for safety, with a planned dose range from 10 mg twice a day to 450 mg twice a day through 13 dose levels. Part 1b will evaluate OKN4395 alone and in combination with pembrolizumab administered on day 1 of each 21-day cycle in patients with selected cancer types. Part 1b will comprise 4 cohorts: cohort 1 in sarcoma (OKN4395 alone), cohort 2 in non-small cell lung cancer (NSCLC), cohort 3 in mesothelioma, and cohort 4 in head \& neck squamous cell carcinoma (HNSCC), with cohorts 2 to 4 in combination with pembrolizumab. The monotherapy expansion cohort (Cohort 1) will also be used to choose the optimal dose for further development and to explore the effect of food on the levels of OKN4395 in the blood. The overall study will enrol approximately 166 participants with up to 54 participants to receive OKN4395 alone and 12 participants to receive OKN4395 in combination with pembrolizumab in Part 1a, and 100 participants in Part 1b split: 40 on monotherapy and 60 on combination therapy. The study will be conducted in the US, in the UK and in the EU.
Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, certain medications like systemic steroids, NSAIDs, and drugs affecting gastrointestinal pH or specific enzymes must be stopped before starting the trial. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug OKN4395 + Pembrolizumab for solid tumors?

Research shows that pembrolizumab, one of the drugs in this treatment, has been effective in treating various cancers like advanced melanoma and non-small-cell lung cancer by helping the immune system attack cancer cells.

12345
Is the combination of OKN4395 and Pembrolizumab safe for humans?

Pembrolizumab has been studied in various cancers like ovarian, lung, and bone cancer, showing a safety profile that is generally acceptable, but it can have side effects like fatigue, rash, and diarrhea. However, specific safety data for the combination of OKN4395 and Pembrolizumab is not available in the provided research.

12467
What makes the drug OKN4395 + Pembrolizumab unique for treating solid tumors?

This treatment combines OKN4395 with pembrolizumab, an immune checkpoint inhibitor that helps the immune system attack cancer cells. Pembrolizumab is already used for various cancers, but combining it with OKN4395 may enhance its effectiveness, especially in tumors that are less responsive to immunotherapy alone.

138910

Eligibility Criteria

This trial is for patients with various solid tumors, including lung cancer and mesothelioma. Participants must have a type of tumor that the study targets and be willing to undergo treatment cycles every 21 days. Specific eligibility details are not provided but typically include factors like age, health status, and prior treatments.

Inclusion Criteria

My cancer is confirmed and has spread or is advanced.
My solid tumor cannot be treated with standard options.
I am fully active or can carry out light work.
I have a tumor that can be safely biopsied.
I can take pills without trouble and don't have major stomach issues.

Exclusion Criteria

My cancer has spread to my brain.
I am currently on IV medication for an infection.
I do not have active hepatitis B, C, or HIV.
I am not on drugs that affect stomach acid levels.
I am currently on a steroid treatment.
I am on medication for an autoimmune disease.
My COPD is not stable.
I have a history of bleeding disorders or stomach/intestinal bleeding.

Participant Groups

The trial tests OKN4395 alone or combined with pembrolizumab in treating solid tumors. It's split into two parts: Part 1a explores multiple doses; Part 1b focuses on selected cancers. Doses range from 10 mg to 450 mg twice daily over several levels.
22Treatment groups
Experimental Treatment
Group I: Squamous NSCLCExperimental Treatment2 Interventions
OKN4395 (OBD/MTD combination dose) in combination with pembrolizumab
Group II: Sarcoma food effect cohort 4Experimental Treatment2 Interventions
Fed First Dose and Alternative Dose
Group III: Sarcoma food effect cohort 3Experimental Treatment2 Interventions
Fasted First Dose and Alternative Dose
Group IV: Sarcoma food effect cohort 2Experimental Treatment2 Interventions
Fed First Dose and OBD/MTD Dose
Group V: Sarcoma food effect cohort 1Experimental Treatment2 Interventions
Fasted First Dose and OBD/MTD Dose
Group VI: Malignant MesotheliomaExperimental Treatment2 Interventions
OKN4395 (OBD/MTD combination dose) in combination with pembrolizumab
Group VII: HNSCCExperimental Treatment2 Interventions
OKN4395 (OBD/MTD combination dose) in combination with pembrolizumab
Group VIII: Dose Level 9Experimental Treatment1 Intervention
170 mg BID
Group IX: Dose Level 8Experimental Treatment1 Intervention
130 mg BID
Group X: Dose Level 7Experimental Treatment1 Intervention
100 mg BID
Group XI: Dose Level 6Experimental Treatment1 Intervention
70 mg BID
Group XII: Dose Level 5Experimental Treatment1 Intervention
50 mg BID
Group XIII: Dose Level 4Experimental Treatment1 Intervention
30 mg BID
Group XIV: Dose Level 3Experimental Treatment1 Intervention
20 mg BID
Group XV: Dose Level 2Experimental Treatment1 Intervention
20/10 mg mane/nocte
Group XVI: Dose Level 13Experimental Treatment1 Intervention
450 mg BID
Group XVII: Dose Level 12Experimental Treatment1 Intervention
350 mg BID
Group XVIII: Dose Level 11Experimental Treatment1 Intervention
280 mg BID
Group XIX: Dose Level 10Experimental Treatment1 Intervention
220 mg BID
Group XX: Dose Level 1Experimental Treatment1 Intervention
10 mg BID
Group XXI: Combination Therapy phase 1a cohort 2Experimental Treatment2 Interventions
OKN4395 (at the OBD/MTD for monotherapy) in combination with pembrolizumab
Group XXII: Combination Therapy phase 1a cohort 1Experimental Treatment2 Interventions
OKN4395 (at one dose level below the OBD/MTD for monotherapy) in combination with pembrolizumab

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
Precision NextGen Oncology and Research CenterBeverly Hills, CA
Sarcoma Oncology CenterSanta Monica, CA
Loading ...

Who is running the clinical trial?

EpkinLead Sponsor
Precision For MedicineIndustry Sponsor

References

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. [2019]To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial.
Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. [2023]To systematically evaluate the efficacy and safety of pembrolizumab (PD-1/PD-L inhibitor) and adjuvant chemotherapy to treat NSCLC and provide evidence-based reference for clinical use.
Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. [2018]Pembrolizumab is a fully humanized anti-PD-1 agent currently approved for the treatment of advanced melanoma and pretreated non-small-cell lung cancer (NSCLC).
[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer]. [2017]Pembrolizumab, a humanized monoclonal antibody IgG4 anti-PD-1, having offered promising results in patients suffering from non-small cell lung cancer metastatic and heavily pretreated.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. [2022]The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. [2021]The KEYNOTE-024 trial demonstrated that pembrolizumab, a PD-1 inhibitor, significantly improves progression-free survival (PFS) and overall survival (OS) in selected patients with previously untreated advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥50% and without EGFR/ALK aberrations. The main aim of this study was to report the efficacy and safety profile of pembrolizumab in real-life conditions.
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. [2022]To evaluate the activity and safety of the PD-1 antibody pembrolizumab in adult patients with advanced osteosarcoma.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50. [2020]Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. [2022]The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of pembrolizumab at doses of 2 mg/kg and 10 mg/kg every 3 weeks in patients with ipilimumab-refractory advanced melanoma.
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. [2023]Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to restore an anti-tumor immune response of T cells. Pembrolizumab is one of the most advanced immune checkpoint inhibitors for cancer care. Apart from rare and serious adverse effects, its favorable tolerance profile enables to treat fragile patients who have often no other choice than best supportive care. The effective retained dose of pembrolizumab is a venous administration of 200 mg every 3 weeks until disease progression, intolerance or up to 24 months. Pembrolizumab has already proven its efficacy and thus obtained marketing authorization in so-called hot or hypermutated tumors or tumors expressing PD-L1 such as melanomas, non-small cell lung cancers, urothelial carcinomas, cervical cancer, etc. Pembrolizumab is also authorized in the United States in the treatment of mismatch repair-deficient tumors or with microsatellite instability. The current challenge is to expand its use in tumor types that are supposed to be less immunogenic, for example, by attempting to warm up the tumor microenvironment, or by combining pembrolizumab with other molecules. An acceptable toxicity profile of such combinations remains to explore. We review here the current indications of this drug, the main prognostic and predictive factors of its efficacy as well as the potential forthcoming indications.